Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation
- PMID: 37229802
- DOI: 10.1016/j.biopha.2023.114916
Advancing therapeutic strategies for Epstein-Barr virus-associated malignancies through lytic reactivation
Abstract
Epstein-Barr virus (EBV) is a widespread human herpes virus associated with lymphomas and epithelial cell cancers. It establishes two separate infection phases, latent and lytic, in the host. Upon infection of a new host cell, the virus activates several pathways, to induce the expression of lytic EBV antigens and the production of infectious virus particles. Although the carcinogenic role of latent EBV infection has been established, recent research suggests that lytic reactivation also plays a significant role in carcinogenesis. In this review, we summarize the mechanism of EBV reactivation and recent findings about the role of viral lytic antigens in tumor formation. In addition, we discuss the treatment of EBV-associated tumors with lytic activators and the targets that may be therapeutically effective in the future.
Keywords: Carcinogenesis; EBV; Lytic reactivation; Therapies.
Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest All authors of this paper have read and approved the final version submitted And the authors declare no conflict of interest The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
